AC Immune

ACIU NASDAQ
5.31
-0.27
-4.84%
休市 16:00 08/23 EDT
开盘
5.57
昨收
5.58
最高
5.64
最低
5.28
成交量
7.35万
成交均量(3M)
9.69万
52周最高
12.50
52周最低
3.250
换手率
0.11%
市值
3.59亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供AC Immune ACIU股票价格,AC Immune股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
展开 >

最近浏览

名称
价格
涨跌幅